Pharmaceutical Industry 27 July – 2 Aug: Ft Lundbeck and GSK

• Lundbeck has secured FDA Fast Track designation for Lu AH69593, an oral orexin 2 receptor agonist being developed for narcolepsy.
• GSK has received early FDA approval for Jideytro, also known as zidesamtinib, for certain adults with advanced ROS1-positive non-small cell lung cancer.

Two significant regulatory developments have placed Lundbeck and GSK at the centre of pharmaceutical innovation across neurology and oncology, with the companies advancing treatments designed around clearly defined biological targets.

Lundbeck has received Fast Track designation from the US Food and Drug Administration for Lu AH69593, its lead oral orexin 2 receptor agonist for narcolepsy. Meanwhile, GSK has secured FDA approval for Jideytro, or zidesamtinib, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor.

Although the programmes address very different conditions, they share an increasingly important pharmaceutical development principle: understanding the biological mechanism of disease and designing medicines capable of acting on it with greater precision.

Lundbeck Targets the Biology Behind Wakefulness

Lu AH69593 was discovered by Lundbeck and is currently being evaluated in phase 1b clinical studies. The oral compound has been designed to activate the orexin 2 receptor, a receptor considered central to the regulation of wakefulness and the stability of the sleep-wake cycle.

Narcolepsy is a chronic neurological disorder that affects the brain’s ability to regulate sleep and wakefulness. It can cause excessive daytime sleepiness, sudden sleep attacks, fragmented nighttime sleep, sleep paralysis and hallucinations.

People living with narcolepsy type 1 may also experience cataplexy, a sudden loss of muscle control that can be triggered by strong emotions. Together, these symptoms can affect education, employment, social relationships, personal independence and overall quality of life.

The condition’s consequences therefore extend well beyond simply feeling tired. The inability to reliably maintain wakefulness can shape almost every part of a person’s daily routine, from travelling safely to participating fully at work or school.

Current treatments can help control individual symptoms, but many patients continue to experience a considerable disease burden. Lundbeck is seeking to address that remaining need by targeting a pathway directly connected to the biological regulation of wakefulness.

Understanding the Orexin Pathway

Orexin is a wake-promoting neuropeptide that plays a central role in stabilising sleep and wakefulness. Orexin-producing neurons connect with multiple areas of the brain involved in arousal, alertness and the regulation of rapid eye movement sleep.

Orexin signalling operates through two receptors. Of these, the orexin 2 receptor is regarded as particularly important to wake-promoting activity and sleep-wake regulation.

Disruption of the orexin system is therefore considered a relevant therapeutic target for narcolepsy and potentially for other conditions characterised by excessive daytime sleepiness.

Lu AH69593 is intended to activate the orexin 2 receptor and strengthen wake-promoting signalling through the orexin pathway. Rather than only managing the outward effects of narcolepsy, Lundbeck’s approach is designed to act on a mechanism closely associated with the underlying biology of the condition.

The development objective is to help restore wakefulness and improve sleep-wake regulation for people living with narcolepsy. Whether the molecule can deliver that outcome will need to be established through further clinical development, but the FDA designation reflects the potential importance of the programme.

Fast Track Designation Offers a More Direct Regulatory Path

The FDA’s Fast Track process is intended to support the development and accelerate the review of medicines being investigated for serious conditions where significant unmet medical needs remain.

The designation can enable more frequent communication between a pharmaceutical developer and the FDA, helping potential development or regulatory issues to be addressed earlier. It may also create opportunities for other expedited review processes where the relevant criteria are met.

Lundbeck’s executive vice president for research and development described the designation as an important milestone for Lu AH69593 and for the company’s wider ambition to translate orexin biology into new treatments for narcolepsy and other sleep-wake disorders.

The company said the designation recognised both the continuing need for innovative narcolepsy therapies and the potential of Lu AH69593. 

Lundbeck also highlighted the programme as an example of its efforts to transform its research pipeline around breakthrough neurology, neuroendocrine and rare-disease opportunities.

Closer engagement with the FDA could now help Lundbeck navigate the next stages of development as it works to determine the compound’s safety, dosing profile, pharmacological activity and potential clinical benefits.

GSK Secures Early Approval for Jideytro

In oncology, GSK has received FDA approval for Jideytro for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously been treated with a ROS1 kinase inhibitor.

The decision was granted ahead of the medicine’s 18 September 2026 target action date and followed previous Breakthrough Therapy and Orphan Drug designations.

Jideytro was brought into GSK’s portfolio through its acquisition of Nuvalent. The medicine was developed to address continuing efficacy and tolerability challenges associated with ROS1-positive lung cancer, including resistance mutations and the spread of cancer to the brain.

Its next-generation design is intended to deliver high selectivity for its molecular target, broad activity against ROS1 resistance mutations and the ability to cross the blood-brain barrier.

This combination is particularly important in ROS1-positive disease because patients may receive treatment for extended periods. Around 50,000 people worldwide are diagnosed with ROS1-positive non-small cell lung cancer each year, with the disease frequently affecting non-smokers in mid-life.

For these patients, a therapy’s long-term tolerability can be almost as important as its immediate antitumour activity. Controlling disease while preserving day-to-day quality of life is a central consideration, particularly when treatment may continue for several years.

ARROS-1 Trial Supports FDA Decision

The FDA approval was based on evidence from ARROS-1, a global, single-arm phase I/II clinical trial involving previously treated patients with ROS1-positive non-small cell lung cancer.

The study demonstrated meaningful and durable responses, including among patients with brain metastases and ROS1 resistance mutations. These are two of the most difficult clinical challenges associated with the disease.

In the overall trial population of 117 patients, Jideytro achieved an objective response rate of 44%. Among responding patients, the duration of response rate was 82% at six months and 69% at 12 months.

These findings indicate that a notable proportion of patients experienced tumour reduction and that many of those responses were sustained over time.

An ARROS-1 investigator said that resistance mutations, disease progression within the brain and treatment-related adverse events continued to create difficulties for patients, despite earlier advances in therapy.

The investigator described the responses recorded in ARROS-1, including those observed in heavily pre-treated patients, as meaningful progress for people living with ROS1-positive lung cancer.

The co-founder and president of patient organisation The ROS1ders also emphasised the importance of quality of life. From a patient perspective, the ambition is not simply to gain more time, but to have quality time in which people can continue living as normally as possible while receiving treatment.

Acquisition Strategy Strengthens GSK’s Oncology Pipeline

GSK’s chief scientific officer said the rapid movement of Jideytro from development to regulatory approval reflected both the strength of the underlying science and the urgent requirement for additional effective and tolerable treatments.

The company believes the approval provides a new option for eligible patients while supporting its strategy of acquiring medicines that act against validated targets and have the potential to improve established standards of care.

The approval also offers an early validation of GSK’s acquisition of Nuvalent. Rather than purchasing an isolated medicine, GSK gained access to a broader pipeline of targeted oncology candidates.

The company is advancing neladalkib for ALK-altered non-small cell lung cancer and NVL-330 for HER2-altered disease. These programmes are progressing alongside the late-stage development of risvutatug rezetecan.

Collectively, these assets give GSK a growing presence in precision lung cancer medicine and could support the development of a more connected oncology portfolio built around molecularly defined patient populations.

Impact on Pharmaceutical Manufacturing and Production

The Lundbeck and GSK developments will create different manufacturing demands, but both illustrate how increasingly targeted medicines are reshaping pharmaceutical production.

As a small-molecule oral medicine, Lu AH69593 could potentially be manufactured using established chemical synthesis and solid-dose production capabilities. 

However, an expedited development pathway may require Lundbeck and its manufacturing partners to prepare clinical supplies, analytical methods, stability programmes and potential scale-up plans in closer coordination with regulatory and clinical activities.

Fast Track designation does not guarantee approval, but it can increase the need for manufacturing readiness. If development progresses positively, Lundbeck may need to ensure that process validation, raw material sourcing, formulation work and commercial capacity planning remain aligned with a potentially accelerated regulatory timetable.

For GSK, the approval of Jideytro moves the focus from clinical supply into sustained commercial production. Manufacturing systems must now support reliable access for a relatively small but globally distributed patient population.

Precision oncology medicines can create particularly complex production and supply chain requirements. Manufacturers must maintain consistent product quality while forecasting demand across narrowly defined genetic subgroups. 

This requires close coordination between production sites, regulatory teams, healthcare systems, diagnostic services and specialist treatment centres.

The approval also places greater importance on companion and molecular diagnostic infrastructure. Patients must be accurately identified as having ROS1-positive disease before the medicine can be prescribed, meaning the success of targeted manufacturing programmes increasingly depends on the wider testing and treatment ecosystem.

As additional medicines from the Nuvalent portfolio advance, GSK may also gain opportunities to apply shared manufacturing platforms, quality systems and supply chain capabilities across several targeted small-molecule cancer treatments.

Targeted Development Becomes a Competitive Advantage

Both announcements demonstrate how clearly defined therapeutic targets can provide pharmaceutical companies with a stronger foundation for research and development.

Lundbeck is focusing on a neurobiological pathway closely associated with wakefulness, while GSK is addressing a specific genetic driver of lung cancer and the resistance mechanisms that can emerge during treatment.

This targeted approach does not eliminate development risk. Lu AH69593 remains in early clinical studies, and Jideytro’s approval applies to a defined group of previously treated patients. 

Nevertheless, both programmes show how detailed disease biology can guide molecule design, patient selection and regulatory strategy.

They also demonstrate the increasing value of expedited regulatory designations. Lundbeck’s Fast Track status may support closer interaction with the FDA during development, while Jideytro’s Breakthrough Therapy and Orphan Drug designations helped signal the medicine’s potential importance before approval.

For pharmaceutical companies, these mechanisms can become central components of development planning, particularly when medicines address serious diseases, smaller patient populations or areas where existing treatments remain insufficient.

Conclusion

Lundbeck’s Fast Track designation for Lu AH69593 and GSK’s approval of Jideytro represent progress at two very different stages of pharmaceutical development.

Lundbeck is beginning the regulatory and clinical journey for a medicine designed to activate the orexin 2 receptor and address the biology behind narcolepsy. GSK, meanwhile, has taken a targeted ROS1 inhibitor through to approval, offering a new treatment option for previously treated patients with advanced ROS1-positive non-small cell lung cancer.

The developments also highlight two complementary routes to pharmaceutical growth. Lundbeck is generating innovation through internal discovery and a transformed research pipeline, while GSK is using strategic acquisition to strengthen its position in precision oncology.

For patients, the significance lies in the possibility of treatments that are more closely aligned with the mechanisms driving their conditions. 

For pharmaceutical manufacturing and production, the announcements reinforce the need for flexible capacity, accelerated development readiness, dependable global supply chains and closer integration between medicines and diagnostic systems.

From sleep-wake regulation to molecularly targeted cancer care, both companies are demonstrating that the next generation of treatments will increasingly be defined not only by the conditions they address, but by how precisely they engage with the biology behind them.

News Credits:

Lundbeck secures FDA Fast Track for narcolepsy drug

GSK wins US approval for ROS1 lung cancer therapy

Vous aimerez peut-être aussi :

1. Pharmaceutical Industry 20 – 26 July: Ft NICE and EpilepsyGTx
2. Pharmaceutical Industry 13 – 19 July: Ft The Regen4HD and The Scottish Medicines Consortium
3. Pharmaceutical Industry 6 – 12 July: Ft Novartis and AlzeCure Pharma